AMRX
Amneal Pharmaceuticals
Data as of 2026-09-05
Company attributes
Price
Interactive 5-year price history chart for AMRX. Latest close $17.87.
Pillar breakdown
0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)
- QualityProfit margins & asset efficiency87ExceptionalHealth Care median (n=163) 51
- ValuePrice vs fundamentals46AverageHealth Care median (n=163) 51
- GrowthRevenue & earnings trajectory77ExceptionalHealth Care median (n=163) 50
- MomentumRecent price strength88ExceptionalHealth Care median (n=163) 62
- HealthBalance sheet & solvency49AverageHealth Care median (n=163) 56
- ProfitabilityROE, ROA, ROIC54AverageHealth Care median (n=163) 49
- TechnicalTrend & volatility signals59StrongHealth Care median (n=163) 62
- RiskVolatility & drawdown profile69StrongHealth Care median (n=163) 47
Pillars not shown: Sentiment, ML (Phase 5+).
Risk Summary
1 active- Net share issuance — top decile[net_issuance_top_decile]Top-decile net issuance over the trailing year (Pontiff-Woodgate 2008 / Daniel-Titman 2006).
These flags keep the raw composite rank (project Rule 16) but forfeit the entered_top5 badge. Two of them — altman_distress and data_quality_input_corruption — additionally force a cautious recommendation; the others act as Top-5 disqualifiers without dictating the buy/hold/sell label on their own.
- Accruals momentum (Δ TATA > 0.05 over 3y)[accruals_momentum_high]
- Insider sell cluster (Cohen-Malloy-Pomorski 2012)[insider_sell_cluster]
Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.
Fair price check
3 different valuation methods each estimate what AMRX should be worth, then we compare to today's price.
- P/E multiplesOvervaluedthinks it's expensive — estimates $11.19, about 37% below today
- DCF (2-stage)Outlierestimate looks unreliable — estimates $2.18 — likely unreliable
- P/B multiplesOutlierestimate looks unreliable — estimates $0.36 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
- Median fair
- $2.18
- Margin of safety(vs fair value)
- < −99%
- Max (ex-outliers)
- $11.19
- Tangible BVPS
- —
- Extreme P/B estimate
- Extreme DCF estimate
- Majority of methods extreme
- Cross-source price disagreement
- Accruals momentum
- Insider-sell cluster
Median of all applicable methods (current price $17.87). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.
Supporting dataRaw fundamentals & data-quality provenance behind the scores above
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $5.71B |
| Revenue (TTM) | $3.12B |
| Net income (TTM) | $215.32M |
| Operating cash flow (TTM) | $200.78M |
| CapEx (TTM) | $72.94M |
| Free cash flow (TTM)CFO − CapEx | $127.83M |
| Total assets | $3.78B |
| Total liabilities | $0.00 |
| Stockholders' equity | $33.02M |
| Cash & equivalents | $127.64M |
| Shares outstanding | 319.35M |
| EPS (basic) | $0.67 |
| EPS (diluted) | $0.67 |
| P/E ratio (TTM) | 26.50 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-08-06
- Latest period end
- 2026-07-31
- Filing lag
- 30 days
- Missing metrics
- 4(depreciation_and_amortization, interest_expense, dividends_paid, ebitda)
Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.